Medicalgorithmics to increase engagement in key projectsFunding support from BioFund
Due to significantly increased customer interest in Medicalgorithmics’ proprietary solutions, the company (a medtech listed on the Warsaw Stock Exchange) and its largest shareholder, BioFund Capital Management LLC, have decided to make an additional investment in R&D and development teams. This move addresses the rising demand for the company’s products, enhance integration capabilities, accelerate the onboarding of new clients, and intensify customer acquisitions for testing its leading AI-driven software. Medicalgorithmics and BioFund have signed an agreement for additional financing of up to $2.4 million, increasing the total loan value to $5.4 million. It should enable the company to execute its current expansion strategy in addition to achieving profitability in 2026.